The company last month promised cost reductions after its drug pamrevlumab failed two late-stage clinical trials, in the lung-scarring disease idiopathic pulmonary fibrosis and Duchenne muscular dystrophy.
The company last month promised cost reductions after its drug pamrevlumab failed two late-stage clinical trials, in the lung-scarring disease idiopathic pulmonary fibrosis and Duchenne muscular dystrophy.
